{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:19:43Z","timestamp":1795090783761,"version":"4.10.2"},"reference-count":129,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.diabet.2025.101681","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T11:39:37Z","timestamp":1750765177000},"page":"101681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101681_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0002","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2025.101681_bib0003","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3390\/nu13072473","article-title":"Weight loss strategies and the risk of skeletal muscle mass loss","volume":"13","author":"McCarthy","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101681_bib0004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3945\/an.116.014506","article-title":"Preserving healthy muscle during weight loss","volume":"8","author":"Cava","year":"2017","journal-title":"Adv Nutr"},{"key":"10.1016\/j.diabet.2025.101681_bib0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41366-024-01533-3","article-title":"The effect of obesity pharmacotherapy on body composition, including muscle mass","volume":"49","author":"Argyrakopoulou","year":"2025","journal-title":"Int J Obes"},{"key":"10.1016\/j.diabet.2025.101681_bib0006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/ajcn\/nqaa339","article-title":"Relation of body fat mass and fat-free mass to total mortality: results from 7 prospective cohort studies","volume":"113","author":"Sedlmeier","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101681_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70025","article-title":"Sarcopenia","volume":"16","author":"Bloomgarden","year":"2024","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabet.2025.101681_bib0009","doi-asserted-by":"crossref","first-page":"afae052","DOI":"10.1093\/ageing\/afae052","article-title":"The conceptual definition of sarcopenia: delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS)","volume":"53","author":"Kirk","year":"2024","journal-title":"Age Ageing"},{"key":"10.1016\/j.diabet.2025.101681_bib0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.14283\/jfa.2022.30","article-title":"Challenges in the development of drugs for sarcopenia and frailty - report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force","volume":"11","author":"Cesari","year":"2022","journal-title":"J Frailty Aging"},{"key":"10.1016\/j.diabet.2025.101681_bib0011","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes Facts"},{"key":"10.1016\/j.diabet.2025.101681_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S002966511500169X","article-title":"Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity","volume":"74","author":"Wannamethee","year":"2015","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.diabet.2025.101681_bib0013","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-023-00943-z","article-title":"Sarcopenic obesity in older adults: a clinical overview","volume":"20","author":"Prado","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0014","first-page":"339","article-title":"Sarcopenic obesity and weight loss-induced muscle mass loss","volume":"28","author":"Caturano","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.diabet.2025.101681_bib0015","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/cells10081958","article-title":"The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms","volume":"10","author":"Massimino","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.diabet.2025.101681_bib0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/nu16010063","article-title":"Sarcopenia and diabetes: a detrimental liaison of advancing age","volume":"16","author":"Lisco","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101681_bib0017","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2213-8587(25)00061-0","article-title":"Type 2 diabetes and accelerated ageing in skeletal muscle","volume":"13","author":"Henson","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13916","article-title":"How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis","volume":"26","author":"Anyiam","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1573399816666200705210006","article-title":"Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus","volume":"17","author":"Ida","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0020","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/jcsm.12838","article-title":"Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications","volume":"12","author":"Zhang","year":"2021","journal-title":"J Cachexia Sarcopenia Mus"},{"key":"10.1016\/j.diabet.2025.101681_bib0021","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.12998\/wjcc.v9.i33.10064","article-title":"Effects of anti-diabetic drugs on sarcopenia: best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia","volume":"9","author":"Ma","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.diabet.2025.101681_bib0022","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40266-023-01042-4","article-title":"Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia - a narrative review","volume":"40","author":"Witham","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.diabet.2025.101681_bib0023","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101681_bib0024","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101681_bib0025","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.diabet.2025.101681_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study","volume":"73","author":"Moll","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2025.101681_bib0027","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or aladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101681_bib0028","article-title":"The role of glucagon-like peptides in osteosarcopenia","volume":"264","author":"Tufail","year":"2025","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101681_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2024.100335","article-title":"Are lean body mass and fat-free mass the same or different body components? a critical perspective","volume":"15","author":"Heymsfield","year":"2024","journal-title":"Adv Nutr"},{"key":"10.1016\/j.diabet.2025.101681_bib0031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.soard.2024.10.037","article-title":"American society for metabolic and bariatric surgery review of body composition","volume":"21","author":"Carter","year":"2025","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101681_bib0032","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cpf.12874","article-title":"Skeletal muscle estimation: a review of techniques and their applications","volume":"44","author":"Rodriguez","year":"2024","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.diabet.2025.101681_bib0033","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0034","article-title":"Rapid weight loss vs. slow weight loss: which is more effective on body composition and metabolic risk factors?","volume":"15","author":"Ashtary-Larky","year":"2017","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.ijo.0803483","article-title":"Changes in fat-free mass during significant weight loss: a systematic review","volume":"31","author":"Chaston","year":"2007","journal-title":"Int J Obes"},{"key":"10.1016\/j.diabet.2025.101681_bib0036","doi-asserted-by":"crossref","first-page":"bvae164","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.diabet.2025.101681_bib0037","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/nu17010132","article-title":"The etiology of reduced muscle mass with surgical and pharmacological weight loss and the identification of potential countermeasures","volume":"17","author":"Faria","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101681_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdnut.2024.104486","article-title":"Sculpting success: the importance of diet and physical activity to support skeletal muscle health during weight loss with new generation anti-obesity medications","volume":"8","author":"Grosicki","year":"2024","journal-title":"Curr Dev Nutr"},{"key":"10.1016\/j.diabet.2025.101681_bib0039","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae496","article-title":"One year changes in body composition and musculoskeletal health following metabolic\/bariatric surgery","volume":"110","author":"Jassil","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13790","article-title":"Effects of bariatric surgery on muscle strength and quality: a systematic review and meta-analysis","volume":"25","author":"Ibacache-Saavedra","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2025.101681_bib0042","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0043","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/diseases12090204","article-title":"The effect of tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies","volume":"12","author":"Rochira","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.diabet.2025.101681_bib0044","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab"},{"issue":"Suppl 4","key":"10.1016\/j.diabet.2025.101681_bib0046","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0047","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1111\/dom.15913","article-title":"Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: filling the gaps","volume":"26","author":"Dubin","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0048","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101681_bib0049","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.metabol.2014.05.008","article-title":"Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells","volume":"63","author":"Li","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2025.101681_bib0050","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41366-019-0513-y","article-title":"Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice","volume":"44","author":"Xu","year":"2020","journal-title":"Int J Obes"},{"key":"10.1016\/j.diabet.2025.101681_bib0051","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.3390\/ijms25158214","article-title":"Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review","volume":"25","author":"Szekeres","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2025.101681_bib0052","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41366-022-01114-2","article-title":"Incretin-induced changes in the transcriptome of skeletal muscles of fa\/fa Zucker rat (ZFR) with obesity, without diabetes","volume":"46","author":"Colin","year":"2022","journal-title":"Int J Obes"},{"key":"10.1016\/j.diabet.2025.101681_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102479","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin","volume":"89","author":"Chan","year":"2024","journal-title":"Tissue Cell"},{"key":"10.1016\/j.diabet.2025.101681_bib0054","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"J Cachexia Sarcopenia Mus"},{"key":"10.1016\/j.diabet.2025.101681_bib0055","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.diabet.2025.101681_bib0056","first-page":"zbaf060","article-title":"Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells","author":"Mukai","year":"2025","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.diabet.2025.101681_bib0057","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JCMA.0000000000000807","article-title":"Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy","volume":"86","author":"Fan","year":"2023","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.diabet.2025.101681_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111472","article-title":"Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats","volume":"539","author":"Yamada","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2025.101681_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.108975","article-title":"Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway","volume":"39","author":"Xu","year":"2025","journal-title":"J Diabetes Complic"},{"key":"10.1016\/j.diabet.2025.101681_bib0061","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.2147\/DDDT.S381546","article-title":"An effective glucagon-like peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism","volume":"16","author":"Ren","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.diabet.2025.101681_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166770","article-title":"Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice","volume":"1869","author":"Iwai","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.diabet.2025.101681_bib0063","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/oby.24274","article-title":"Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle","volume":"33","author":"Choi","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.diabet.2025.101681_bib0064","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9926462","article-title":"Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts","volume":"2023","author":"Deng","year":"2023","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0065","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.18632\/aging.203546","article-title":"Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice","volume":"13","author":"Khin","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.diabet.2025.101681_bib0066","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2020.00090","article-title":"Preventive effects of dulaglutide on disuse muscle atrophy through inhibition of inflammation and apoptosis by induction of Hsp72 expression","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2025.101681_bib0067","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/jcsm.13524","article-title":"Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation","volume":"15","author":"Huang","year":"2024","journal-title":"J Cachexia Sarcopenia Mus"},{"key":"10.1016\/j.diabet.2025.101681_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0069","article-title":"The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachexia Sarcopenia Mus"},{"key":"10.1016\/j.diabet.2025.101681_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.diabet.2025.101681_bib0071","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0072","article-title":"Glucagon-like peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: from mechanisms of action to clinical applications","volume":"15","author":"Rajagopal","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.diabet.2025.101681_bib0073","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.orcp.2025.01.009","article-title":"Effects of liraglutide on body composition in people living with obesity or overweight: a systematic review","volume":"19","author":"Schmidt","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101681_bib0074","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.23098","article-title":"Liraglutide does not adversely impact fat-free mass loss","volume":"29","author":"Grannell","year":"2021","journal-title":"Obesity"},{"key":"10.1016\/j.diabet.2025.101681_bib0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14740\/jocmr3647","article-title":"Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series","volume":"11","author":"Ishii","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.diabet.2025.101681_bib0076","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. a perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.diabet.2025.101681_bib0077","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2025.101681_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus","volume":"15","author":"Rodriguez Jimenez","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14740\/jocmr4987","article-title":"Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes","volume":"15","author":"Uchiyama","year":"2023","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.diabet.2025.101681_bib0081","first-page":"9908","article-title":"Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults","volume":"27","author":"Xiang","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.diabet.2025.101681_bib0082","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/medicines9090047","article-title":"The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study","volume":"9","author":"Ozeki","year":"2022","journal-title":"Medicines"},{"key":"10.1016\/j.diabet.2025.101681_bib0083","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/cid\/ciae384","article-title":"Effects of semaglutide on muscle structure and function in the SLIM LIVER study","volume":"80","author":"Ditzenberger","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diabet.2025.101681_bib0084","first-page":"98","article-title":"Skeletal muscle mass and body weight fall proportionally with use of dual glucagon-like peptide 1\/glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide: case report and review of literature","volume":"11","author":"Zinn","year":"2025","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.diabet.2025.101681_bib0085","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/nu17071216","volume":"17","author":"Schiavo","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101681_bib0086","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0087","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2015.0365","article-title":"The effect of intramuscular fat on skeletal muscle mechanics: implications for the elderly and obese","volume":"12","author":"Rahemi","year":"2015","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.diabet.2025.101681_bib0088","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J Cachexia Sarcopenia Mus"},{"key":"10.1016\/j.diabet.2025.101681_bib0089","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038444","article-title":"Favorable liver and skeletal muscle changes in patients with MASLD and T2D receiving glucagon-like peptide-1 receptor agonist: a prospective cohort study","volume":"103","author":"Kakegawa","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.diabet.2025.101681_bib0090","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.24.31805","article-title":"Intrapatient changes in CT-based body composition after initiation of semaglutide (glucagon-like peptide-1 receptor agonist) therapy","volume":"223","author":"Nelson","year":"2024","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.diabet.2025.101681_bib0091","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0092","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2337\/db18-673-P","article-title":"Novel approach to sarcopenia in diabetic patients treated with GLP-1 receptor agonists (GLP-1RA) (abstract)","volume":"67","author":"Ikejima","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101681_bib0093","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.diabet.2025.101681_bib0094","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1152\/physrev.2000.80.2.649","article-title":"Human body composition: in vivo methods","volume":"80","author":"Ellis","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40520-016-0717-0","article-title":"Measurement of muscle mass in sarcopenia: from imaging to biochemical markers","volume":"29","author":"Tosato","year":"2017","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.diabet.2025.101681_bib0096","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s11695-020-05082-2","article-title":"Measuring muscle mass and strength in obesity: a review of various methods","volume":"31","author":"Sizoo","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101681_bib0097","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/S0029665115000129","article-title":"Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia","volume":"74","author":"Heymsfield","year":"2015","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.diabet.2025.101681_bib0098","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/CIA.S443572","article-title":"Imaging of sarcopenia in type 2 diabetes mellitus","volume":"19","author":"Wang","year":"2024","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.diabet.2025.101681_bib0099","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jcsm.12268","article-title":"Pitfalls in the measurement of muscle mass: a need for a reference standard","volume":"9","author":"Buckinx","year":"2018","journal-title":"J Cachexia Sarcopenia Mus"},{"key":"10.1016\/j.diabet.2025.101681_bib0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000499607","article-title":"Limitations of fat-free mass for the assessment of muscle mass in obesity","volume":"12","author":"Jensen","year":"2019","journal-title":"Obes Facts"},{"key":"10.1016\/j.diabet.2025.101681_bib0101","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3945\/ajcn.2008.27402","article-title":"Contribution of individual organ mass loss to weight loss-associated decline in resting energy expenditure","volume":"90","author":"Bosy-Westphal","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101681_bib0102","doi-asserted-by":"crossref","first-page":"10028","DOI":"10.1038\/s41598-019-46428-w","article-title":"Changes in DXA-derived lean mass and MRI-derived cross-sectional area of the thigh are modestly associated","volume":"9","author":"Tavoian","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2025.101681_bib0103","doi-asserted-by":"crossref","first-page":"11765","DOI":"10.1038\/s41598-020-68797-3","article-title":"Body composition analysis using CT and MRI: intra-individual intermodal comparison of muscle mass and myosteatosis","volume":"10","author":"Faron","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2025.101681_bib0104","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0105","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1017\/S000711452000224X","article-title":"Effects of gradual weight loss v. rapid weight loss on body composition and RMR: a systematic review and meta-analysis","volume":"124","author":"Ashtary-Larky","year":"2020","journal-title":"Br J Nutr"},{"key":"10.1016\/j.diabet.2025.101681_bib0106","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13370","article-title":"The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis","volume":"23","author":"Nuijten","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105656","article-title":"Worldwide burden of antidiabetic drug-induced sarcopenia: an international pharmacovigilance study","volume":"129","author":"Kong","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.diabet.2025.101681_bib0108","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/dom.16171","article-title":"Relative effects of genetically proxied glucagon-like peptide-1 receptor agonism on muscle and fat mass: a mendelian randomization study","volume":"27","author":"Liang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7570\/jomes22025","article-title":"Assessment of muscle quantity, quality and function","volume":"31","author":"Koo","year":"2022","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.diabet.2025.101681_bib0110","doi-asserted-by":"crossref","DOI":"10.1177\/20503121231214650","article-title":"Relationship between muscle mass and muscle strength with physical performance in older adults: a systematic review","volume":"11","author":"Riviati","year":"2023","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.diabet.2025.101681_bib0111","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/obr.12422","article-title":"Effect of diet-induced weight loss on muscle strength in adults with overweight or obesity - a systematic review and meta-analysis of clinical trials","volume":"17","author":"Zibellini","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0112","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13890","article-title":"Rives-Lange C. Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-a systematic mapping review","volume":"26","author":"Czernichow","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101681_bib0113","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fphys.2020.00963","article-title":"Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the National Institute on","volume":"11","author":"Correa-de-Araujo","year":"2020","journal-title":"Aging Front Physiol"},{"key":"10.1016\/j.diabet.2025.101681_bib0114","article-title":"Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD","volume":"5","author":"Linge","year":"2023","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.diabet.2025.101681_bib0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/gerona\/60.3.324","article-title":"Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons","volume":"60","author":"Visser","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.diabet.2025.101681_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1394506","article-title":"Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice","volume":"15","author":"Pantanetti","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0117","doi-asserted-by":"crossref","DOI":"10.23876\/j.krcp.24.207","article-title":"Sarcopenia, sarcopenic obesity, and frailty in individuals with chronic kidney disease: a comprehensive review","author":"Chao","year":"2025","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101681_bib0118","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078933","article-title":"Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis","volume":"14","author":"Deng","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabet.2025.101681_bib0119","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","article-title":"Sarcopenia and cardiovascular diseases","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101681_bib0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.diabet.2025.101681_bib0121","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101681_bib0122","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cardfail.2024.01.005","article-title":"Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF","volume":"30","author":"Driggin","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2025.101681_bib0123","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.3390\/nu14163266","article-title":"Association between alcohol consumption and the risk of sarcopenia: a systematic review and meta-analysis","volume":"14","author":"Hong","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101681_bib0124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00223-023-01081-4","article-title":"Alcohol consumption and measures of sarcopenic muscle risk: cross-sectional and prospective associations within the UK Biobank study","volume":"113","author":"Skinner","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.diabet.2025.101681_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101612","article-title":"Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0126","doi-asserted-by":"crossref","DOI":"10.1111\/dom.16453","article-title":"Glucagon-like peptide-1 receptor agonists and alcohol use disorders: an emerging unexpected beneficial effect","author":"Scheen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0127","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1210\/clinem\/dgad426","article-title":"Understanding the benefit of combining GLP-1 agonists with exercise: time will tell","volume":"109","author":"Malin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101681_bib0128","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","author":"Ryan","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.diabet.2025.101681_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:45:25Z","timestamp":1753310725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1262363625000758"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101681","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101681"}}